FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Protocols
5

TB-500 dosage timing question

Crew Hudson·6 months ago
Looking for input from experienced users on this topic. I have done a lot of reading but wanted to get real-world perspectives from people who have actually tried different approaches. What has worked best for you?

Comments (8)

Onyx HughesDEMO·8 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Zion BlakeDEMO·8 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Hart ChenDEMO·7 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Jude HoganDEMO·7 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Dale BanksDEMO·6 months ago

I split my TB-500 dose into two injections per week rather than one larger dose. Anecdotally it seemed to provide more consistent results for my elbow tendinopathy. The half-life data suggests it should not matter much but I noticed less of a rollercoaster effect.

0
Hayden ArcherDEMO·6 months ago

Morning vs evening dosing - has anyone compared? I have been doing AM injections because I read somewhere that tissue repair signaling is more active during sleep. So getting the TB-500 circulating before bed might be counterproductive? Or does it even matter at its half-life?

0
Brook AshfordDEMO·6 months ago

The loading phase discussion is important. I did 4 weeks at 5mg/week then dropped to 2.5mg/week maintenance. The loading phase seemed necessary - I did not notice much until week 3 of the higher dose. Skipping it might mean slower onset of results.

0
Cloud BaileyDEMO·6 months ago

One thing worth adding - I found SubQ abdomen gave me better systemic distribution than intramuscular for TB-500 specifically. With BPC-157 I prefer local injection near the injury, but TB-500 seems to work systemically regardless of site.

0

Sign in to comment.